Telix Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio165.02626.21
P/S Ratio10.526.4914.37290.85203.32
P/B Ratio14.5021.9128.751023.7813.41
Price/Tangible Book54.1783.14109.3953.46
Price/FCF286.95229.72619.12
Price/OCF191.44136.63540.78
Enterprise Value Ratios
EV/Revenue10.396.2613.62284.54199.24
EV/EBITDA92.9555.00
EV/EBIT99.4160.60
EV/FCF283.58221.37606.68
Profitability & Returns
Return on Equity (ROE)0.14%0.05%-2.53%-1.98%-0.60%
Return on Assets (ROA)0.05%0.10%-0.25%-0.38%-0.24%
Return on Invested Capital (ROIC)0.30%5.99%-3.47%
Return on Capital Employed (ROCE)0.07%0.21%-0.44%-1.13%-0.36%
Leverage & Solvency Ratios
Debt/Equity1.020.120.131.180.03
Debt/EBITDA6.470.30
Debt/FCF20.251.231.29
Liquidity Ratios
Current Ratio2.781.412.021.254.69
Quick Ratio2.601.181.901.134.62
Efficiency Ratios
Asset Turnover0.811.520.880.060.04
Inventory Turnover10.7915.3610.921.253.44
Yield & Distribution Ratios
Earnings Yield0.01%0.00%-0.05%-0.04%-0.04%
FCF Yield0.00%0.00%-0.03%-0.03%0.00%
Buyback Yield-0.07%-0.04%-0.10%-0.10%-0.10%